Monoacylglycerol lipase modulators

US11891387B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Michael K. Ameriks · San Diego, US
• Brian Ngo Laforteza · San Diego, US
• Suchitra Ravula · San Diego, US
• Jamie M. Schiffer · San Diego, US
• Brice M. Stenne · Village of La Jolla, US

Key dates

• Filing date: Mar 25, 2021
• Grant date: Feb 6, 2024
• Expiry date: Oct 9, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R1a, R1b, R2, and R3, are defined herein.